
    
      Phase II multi-cohort study based on two-stage Simon design. The primary goal of the study is
      response rate at 8 weeks in participants with advanced solid tumors treated with synthetic
      phosphoethanolamine, as defined by Response Evaluation Criteria in Solid Tumors version 1.1
      (RECIST v 1.1) or specific criteria for prostate cancer.
    
  